FY2027 EPS Forecast for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Brookline Capital Acquisition dropped their FY2027 earnings estimates for Kura Oncology in a note issued to investors on Thursday, March 5th. Brookline Capital Acquisition analyst L. Cann now expects that the company will post earnings of $0.31 per share for the year, down from their prior forecast of $0.32. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Acquisition also issued estimates for Kura Oncology’s FY2028 earnings at $3.59 EPS, FY2029 earnings at $11.61 EPS and FY2030 earnings at $26.58 EPS.

A number of other research analysts have also recently commented on KURA. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Barclays reissued an “overweight” rating and issued a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Tuesday, January 13th. Wedbush dropped their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Leerink Partners set a $20.00 target price on shares of Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.71.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $8.96 on Monday. The company has a current ratio of 6.06, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $9.43. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $12.49. The firm has a market cap of $791.44 million, a price-to-earnings ratio of -2.82 and a beta of 0.22.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.The company had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million.

Insider Transactions at Kura Oncology

In other news, insider Francis Burrows sold 23,726 shares of Kura Oncology stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.78, for a total value of $232,040.28. Following the completion of the transaction, the insider directly owned 33,735 shares in the company, valued at approximately $329,928.30. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 7,142 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $60,421.32. Following the sale, the senior vice president owned 145,167 shares in the company, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of KURA. IFP Advisors Inc lifted its holdings in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after buying an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after acquiring an additional 3,072 shares during the period. Allworth Financial LP grew its stake in Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the period.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.